020 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis: 6 study years
Conclusions
After 6 years of follow-up, rates of patients with CDP24 and risk of requiring a walking aid remained lower in earlier initiators of ocrelizumab (OCR-OCR) versus those initially receiving IFN (IFN-OCR), demonstrating maintained benefits of earlier treatment with ocrelizumab.
g.giovannoni@qmul.ac.uk
Source: Journal of Neurology, Neurosurgery and Psychiatry - Category: Neurosurgery Authors: Giovannoni, G., Kappos, L., Seze, J. d., Hauser, S. L., Overell, J., Koendgen, H., Prajapati, K., Manfrini, M., Wang, Q., Wolinsky, J. S. Tags: Poster Presentations Source Type: research
More News: Avonex | Brain | Disability | Multiple Sclerosis | Neurology | Neurosurgery | Psychiatry | Rebif | Study